{"id":44597,"date":"2022-06-02T02:01:22","date_gmt":"2022-06-02T00:01:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/"},"modified":"2022-06-02T02:01:22","modified_gmt":"2022-06-02T00:01:22","slug":"accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/","title":{"rendered":"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer"},"content":{"rendered":"<div>\n<p>BROOKLYN, N.Y.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.accutarbio.com&amp;esheet=52737350&amp;newsitemid=20220601006281&amp;lan=en-US&amp;anchor=Accutar+Biotechnology%2C+Inc.&amp;index=1&amp;md5=2fc974818821960048e9c899a51e6e5d\" rel=\"nofollow noopener\" shape=\"rect\">Accutar Biotechnology, Inc.<\/a>, a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen receptor signaling inhibitors. AC0176 is an orally bioavailable, chimeric degrader molecule targeting the androgen receptor (AR). AC0176 is currently being evaluated in a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with mCRPC.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220601006281\/en\/1474223\/5\/accutar-logo-l.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220601006281\/en\/1474223\/21\/accutar-logo-l.jpg\"><\/a><\/p>\n<p>\n\u201cmCRPC is a devastating cancer for men marked by high recurrence rate and poor survival. Receiving Fast Track designation from the FDA highlights the high unmet medical need for mCRPC and acknowledges the potential of AC0176 as a novel treatment for this patient population,\u201d said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. &#8220;AC0176 was designed to potently degrade both AR wildtype and prevalent AR mutations which confer drug resistance to current AR signaling inhibitors. We look forward to continued interaction with FDA as we quickly advance the development of this potentially promising treatment option for patients in need.\u201d\n<\/p>\n<p>\n<strong>About Metastatic Castration-Resistant Prostate Cancer (mCRPC)<\/strong>\n<\/p>\n<p>\nProstate cancer (PC) is the second most commonly diagnosed cancer among men worldwide, and the first among men in the United States. mCRPC is a lethal diagnosis, and more effective therapeutic approaches are urgently needed for patients, particularly those who progressed on AR signaling inhibitors. AR-reactivating mechanisms conferring resistance to AR signaling inhibitors include, AR amplification and overexpression, AR point mutations, AR splicing variants, intra-tumoral androgen synthesis, promiscuous AR activation by other factors, etc.\n<\/p>\n<p>\n<strong>About AC0176<\/strong>\n<\/p>\n<p>\nAC0176 is an investigational orally bioavailable, chimeric degrader of AR for the potential treatment of prostate cancers. In preclinical studies, AC0176 demonstrated potent and selective AR protein degradation, favorable pharmacological properties, as well as promising anti-tumor activity in animal models. AC0176 was designed to have broad coverage of AR wildtype and prevalent AR mutations, including but not limited to L702H, T878A, H875Y, W742C. AC0176 is being evaluated in a Phase 1 clinical trial, and information on the study can be found on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DpabsKoKv9Q3IsVIMCyvquEtswC8OGPmHklLETuZ9VtWGnPzqfjxvQnsfXz3vkSnGFKB3h1zVKH68TFI2VtiyhYJxOtHisrrre2vp1421_Rg%3D&amp;esheet=52737350&amp;newsitemid=20220601006281&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=2&amp;md5=5a10dd3d4e7a3e5ec0ed8cc6a8086cc5\" rel=\"nofollow noopener\" shape=\"rect\">www.clinicaltrials.gov<\/a> (NCT05241613).\n<\/p>\n<p>\n<strong>About Accutar Biotechnology, Inc.<\/strong>\n<\/p>\n<p>\nAccutar is a clinical stage biotech company focused on AI-enabled drug discovery, and its application to the discovery and development of clinically differentiated medicines.\n<\/p>\n<p>\nBe transformative. For patients.\n<\/p>\n<p>\nTo learn more about Accutar, please visit us at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.accutarbio.com%2F&amp;esheet=52737350&amp;newsitemid=20220601006281&amp;lan=en-US&amp;anchor=www.accutarbio.com&amp;index=3&amp;md5=fb649d89ca3aacd9d23533a6bb93ca6c\" rel=\"nofollow noopener\" shape=\"rect\">www.accutarbio.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For More Information:<\/b><br \/>Jiaqi Ren<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#109;&#x65;d&#105;&#x61;&#64;&#97;&#x63;&#x63;&#117;&#x74;&#x61;r&#98;&#x69;o&#46;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#x65;&#100;&#105;a&#64;&#x61;&#x63;&#x63;&#117;ta&#x72;&#x62;&#x69;&#111;&#46;c&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BROOKLYN, N.Y.&#8211;(BUSINESS WIRE)&#8211;Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44597","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BROOKLYN, N.Y.&#8211;(BUSINESS WIRE)&#8211;Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-02T00:01:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220601006281\/en\/1474223\/21\/accutar-logo-l.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer\",\"datePublished\":\"2022-06-02T00:01:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/\"},\"wordCount\":446,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220601006281\\\/en\\\/1474223\\\/21\\\/accutar-logo-l.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/\",\"name\":\"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220601006281\\\/en\\\/1474223\\\/21\\\/accutar-logo-l.jpg\",\"datePublished\":\"2022-06-02T00:01:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220601006281\\\/en\\\/1474223\\\/21\\\/accutar-logo-l.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220601006281\\\/en\\\/1474223\\\/21\\\/accutar-logo-l.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Pharma Trend","og_description":"BROOKLYN, N.Y.&#8211;(BUSINESS WIRE)&#8211;Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-02T00:01:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220601006281\/en\/1474223\/21\/accutar-logo-l.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer","datePublished":"2022-06-02T00:01:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/"},"wordCount":446,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220601006281\/en\/1474223\/21\/accutar-logo-l.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/","url":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/","name":"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220601006281\/en\/1474223\/21\/accutar-logo-l.jpg","datePublished":"2022-06-02T00:01:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220601006281\/en\/1474223\/21\/accutar-logo-l.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220601006281\/en\/1474223\/21\/accutar-logo-l.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44597"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44597\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}